EFFICACY OF AN ANALYSIS OF LYMPHOCYTE SUBSETS IN PREDICTING THE CLINICAL-RESPONSE TO ALPHA-INTERFERON THERAPY IN THALASSEMIA PATIENTS WITH CHRONIC INFECTION BY HEPATITIS-C VIRUS - A PILOT-STUDY

被引:7
作者
RUSSOMANCUSO, G [1 ]
DIGREGORIO, F [1 ]
PASSERO, E [1 ]
SCIOTTO, A [1 ]
MAZZARINO, MC [1 ]
MALAPONTE, G [1 ]
SCHILIRO, G [1 ]
机构
[1] UNIV CATANIA,INST GEN PATHOL,CATANIA,ITALY
关键词
ALPHA-INTERFERON; HEPATITIS C VIRUS; LYMPHOCYTE SUBSETS; NATURAL KILLER CELLS; THALASSEMIA;
D O I
10.1111/j.1365-2141.1995.tb03303.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
alpha-interferon (alpha-IFN) has been used to treat chronic non-A non-B hepatitis in thalassaemic patients with response rates from 45% to 83%. Unfortunately treatment with alpha-IFN is associated with side-effects which have a negative effect on the quality of life of the patient. Therefore it would be useful if we could distinguish in advance those patients who would benefit from such therapy from those who would not. In the present study we found that the modification of lymphocyte subsets 20 h after the administration of the first dose of alpha-IFN revealed that relative numbers of T helper lymphocytes (CD4(+)) increased in three non-responding patients and decreased in five responding patients, whereas those of T suppressor lymphocytes (CD8(+)), and natural killer cells (CD57(+), CD16(+)) decreased in nonresponding patients and increased in responding patients. Therefore analysis of the lymphocyte subsets CD4, CD8, CD57 and CD16 before and 20 h after the administration of alpha-IFN can be used to predict the clinical response to treatment with alpha-IFN.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 48 条
[1]  
AKBAR AN, 1987, CLIN EXP IMMUNOL, V70, P345
[2]  
AKBAR AN, 1986, J IMMUNOL, V136, P1635
[3]   IRON STATE AND HEPATIC-DISEASE IN PATIENTS WITH THALASSEMIA MAJOR, TREATED WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINE [J].
ALDOURI, MA ;
WONKE, B ;
HOFFBRAND, AV ;
FLYNN, DM ;
LAULICHT, M ;
FENTON, LA ;
SCHEUER, PJ ;
KIBBLER, CC ;
ALLWOOD, CA ;
BROWN, D ;
THOMAS, HC .
JOURNAL OF CLINICAL PATHOLOGY, 1987, 40 (11) :1353-1359
[4]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[5]   SIGNIFICANCE OF IGM ANTIBODY TO HEPATITIS-C VIRUS IN PATIENTS WITH CHRONIC HEPATITIS-C [J].
BRILLANTI, S ;
MASCI, C ;
RICCI, P ;
MIGLIOLI, M ;
BARBARA, L .
HEPATOLOGY, 1992, 15 (06) :998-1001
[6]   A PATTERN OF 5-1-1 AND C100-3 ONLY ON HEPATITIS-C VIRUS (HCV) RECOMBINANT IMMUNOBLOT ASSAY DOES NOT REFLECT HCV INFECTION IN BLOOD-DONORS [J].
BUSCH, MP ;
TOBLER, L ;
QUAN, S ;
WILBER, JC ;
JOHNSON, P ;
POLITO, A ;
STEANE, E ;
ZOLA, A ;
BAHL, C ;
NELLES, M ;
LEE, SR .
TRANSFUSION, 1993, 33 (01) :84-88
[7]  
COLOMBO M, 1989, LANCET, V2, P1006
[8]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[9]   INTERFERON IN VIRAL-HEPATITIS - ROLE IN PATHOGENESIS AND TREATMENT [J].
DAVIS, GL ;
HOOFNAGLE, JH .
HEPATOLOGY, 1986, 6 (05) :1038-1041
[10]   RECOMBINANT ALPHA-INTERFERON TREATMENT OF NON-A, NON-B (TYPE-C) HEPATITIS - REVIEW OF STUDIES AND RECOMMENDATIONS FOR TREATMENT [J].
DAVIS, GL .
JOURNAL OF HEPATOLOGY, 1990, 11 :S72-S77